EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Pharmacologic and Non-Pharmacologic Interventions for Hypothalamic Obesity: An Updated Review

Anna Zenno, Melinda Pierce

Current Obesity Reports · 24.07.2026 · 15 (1)

DOI: 10.1007/s13679-026-00744-1 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Obesity Reports, online erschienen am 24.07.2026. Verfasst von Anna Zenno und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of Washington School of Medicine, 4800 Sand Point Way NE, M/S OC.7.820, PO Box 5371, WA, Seattle, 98145, USA. an…. Hauptthemen laut MEDLINE: Obesity, Anti-Obesity Agents, Hypothalamic Diseases. Die Arbeit nennt 48 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose of Review This review aims to provide a summary of treatment strategies for hypothalamic obesity (HO) and the latest data on pharmacologic interventions for HO. Recent Findings We summarize new consensus diagnostic criteria for acquired HO, non-pharmacologic interventions such as diet and physical activity, medications including the newly FDA approved setmelanotide, metabolic and bariatric surgery, and emerging treatment strategies that address the complex pathophysiology of HO. Summary Hypothalamic obesity is caused by hypothalamic injury that impairs energy balance, metabolism, and satiety and leads to refractory obesity that is resistant to traditional diet and exercise interventions. Despite recent progress, effective long-term management of HO remains challenging, with few controlled trials, significant heterogeneity in patient response, and lack of long-term follow up data. A new medication targeting the melanocortin-4 receptor (MC4R) pathway was recently approved for treatment with additional newer drugs in development [1].

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityAnti-Obesity AgentsHypothalamic DiseasesHumansBariatric SurgeryReceptor, Melanocortin, Type 4alpha-MSHHypothalamusEnergy MetabolismExercise

Stichwörter der Autor:innen

Drug treatmentHypothalamic injuryLifestyle interventionObesitySurgery

Substanzen

Anti-Obesity AgentsReceptor, Melanocortin, Type 4alpha-MSH

Autor:innen und Institutionen

  • Department of Pediatrics, University of Washington School of Medicine, 4800 Sand Point Way NE, M/S OC.7.820, PO Box 5371, WA, Seattle, 98145, USA. annaz24@uw.edu.
  • Department of Medicine, University of Washington School of Medicine, 4800 Sand Point Way NE, M/S OC.7.820, PO Box 5371, Seattle, WA, 98145, USA. annaz24@uw.edu.
  • Department of Pediatrics, University of Washington School of Medicine, 4800 Sand Point Way NE, M/S OC.7.820, PO Box 5371, WA, Seattle, 98145, USA.

Zitieren

APA

Zenno, A., & Pierce, M. (2026). Pharmacologic and Non-Pharmacologic Interventions for Hypothalamic Obesity: An Updated Review. Current Obesity Reports, 15(1). https://doi.org/10.1007/s13679-026-00744-1

Vancouver

Zenno A, Pierce M. Pharmacologic and Non-Pharmacologic Interventions for Hypothalamic Obesity: An Updated Review. Current Obesity Reports. 2026;15(1). doi:10.1007/s13679-026-00744-1

BibTeX
@article{Zenno2026,
  author = {Zenno, Anna and Pierce, Melinda},
  title = {Pharmacologic and Non-Pharmacologic Interventions for Hypothalamic Obesity: An Updated Review},
  journal = {Current Obesity Reports},
  year = {2026},
  volume = {15},
  number = {1},
  doi = {10.1007/s13679-026-00744-1}
}
Kostenlos starten →